Home / Companies / News / Hetero joins long list of firms to launch Covid-19 drug favipiravir

Hetero joins long list of firms to launch Covid-19 drug favipiravir

Will sell its oral anitiviral for Rs 59 a pill, Cipla and DRL to launch soon

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2

Premium

2 min read Last Updated : Jul 29 2020 | 5:55 PM IST

Joining the long list of firms to launch its own brand of oral antiviral drug favipiravir, Hyderabad's Hetero on Wednesday said that it would market the drug under Favivir brand priced at Rs 59 per tablet.

Hetero has priced its brand in between Glenmark's FabiFlu (Rs 79 per tablet) and the yet to be launched Cipla's Ciplenza (around Rs 68 per tablet). Glenmark was the first to launch the drug. Hetero Healthcare would distribute the brand and it is available from today at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.

Already a

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in